China NMPA Drug Inspection - Fujian Mingyuan Pharmaceutical Co., Ltd. - Celosia argentea
China NMPA drug inspection for Fujian Mingyuan Pharmaceutical Co., Ltd. published March 27, 2019. Drug: Celosia argentea. The Fujian Province Drug Quality Announcement, issued on March 27, 2019, detailed the findings from the 2018 drug sampli
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Fujian Mingyuan Pharmaceutical Co., Ltd. published March 27, 2019. Drug: Celosia argentea. The Fujian Province Drug Quality Announcement, issued on March 27, 2019, detailed the findings from the 2018 drug sampli
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox